{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:29:10Z","timestamp":1794443350569,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Hyperpolarized (HP) <jats:sup>13<\/jats:sup>C-pyruvate MRI is a stable-isotope molecular imaging modality that provides real-time assessment of the rate of metabolism through glycolytic pathways in human prostate cancer. Heretofore this imaging modality has been successfully utilized in prostate cancer only in localized disease. This pilot clinical study investigated the feasibility and imaging performance of HP <jats:sup>13<\/jats:sup>C-pyruvate MR metabolic imaging in prostate cancer patients with metastases to the bone and\/or viscera.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Six patients who had metastatic castration-resistant prostate cancer were recruited. Carbon-13 MR examination were conducted on a clinical 3T MRI following injection of 250\u2009mM hyperpolarized <jats:sup>13<\/jats:sup>C-pyruvate, where pyruvate-to-lactate conversion rate (<jats:italic>k<\/jats:italic><jats:sub>PL<\/jats:sub>) was calculated. Paired metastatic tumor biopsy was performed with histopathological and RNA-seq analyses.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>We observed a high rate of glycolytic metabolism in prostate cancer metastases, with a mean <jats:italic>k<\/jats:italic><jats:sub>PL<\/jats:sub> value of 0.020\u2009\u00b1\u20090.006\u2009(s<jats:sup>\u22121<\/jats:sup>) and 0.026\u2009\u00b1\u20090.000\u2009(s<jats:sup>\u22121<\/jats:sup>) in bone (<jats:italic>N<\/jats:italic>\u2009=\u20094) and liver (<jats:italic>N<\/jats:italic>\u2009=\u20092) metastases, respectively. Overall, high <jats:italic>k<\/jats:italic><jats:sub>PL<\/jats:sub> showed concordance with biopsy-confirmed high-grade prostate cancer including neuroendocrine differentiation in one case. Interval decrease of <jats:italic>k<\/jats:italic><jats:sub>PL<\/jats:sub> from 0.026 at baseline to 0.015\u2009(s<jats:sup>\u22121<\/jats:sup>) was observed in a liver metastasis 2 months after the initiation of taxane plus platinum chemotherapy. RNA-seq found higher levels of the lactate dehydrogenase isoform A (Ldha,15.7\u2009\u00b1\u20090.7) expression relative to the dominant isoform of pyruvate dehydrogenase (Pdha1, 12.8\u2009\u00b1\u20090.9).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>HP <jats:sup>13<\/jats:sup>C-pyruvate MRI can detect real-time glycolytic metabolism within prostate cancer metastases, and can measure changes in quantitative <jats:italic>k<\/jats:italic><jats:sub>PL<\/jats:sub> values following treatment response at early time points. This first feasibility study supports future clinical studies of HP <jats:sup>13<\/jats:sup>C-pyruvate MRI in the setting of advanced prostate cancer.<\/jats:p>\n<\/jats:sec>","DOI":"10.1038\/s41391-019-0180-z","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T19:03:14Z","timestamp":1572894194000},"page":"269-276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2765-1685","authenticated-orcid":false,"given":"Hsin-Yu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Bok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Ohliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy W.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"van Criekinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Slater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4183-3634","authenticated-orcid":false,"given":"Peder E. Z.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kurhanewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Vigneron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"key":"180_CR1","unstructured":"Society AC. Cancer facts and figures 2019. Atlanta, GA: American Cancer Society; 2019."},{"key":"180_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.euf.2016.06.018","volume":"3","author":"AR Padhani","year":"2017","unstructured":"Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F, Collins DJ, et al. Rationale for modernising imaging in advanced prostate cancer. Eur Urol Focus. 2017;3:223\u201339.","journal-title":"Eur Urol Focus"},{"key":"180_CR3","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","volume":"67","author":"ND James","year":"2015","unstructured":"James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with newly diagnosed metastatic prostate cancer in the \u201cDocetaxel Era\u201d: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK\/06\/019). Eur Urol. 2015;67:1028\u201338.","journal-title":"Eur Urol"},{"key":"180_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/pcan.2013.41","volume":"17","author":"OB Goodman Jr.","year":"2014","unstructured":"Goodman OB Jr., Flaig TW, Molina A, Mulders PF, Fizazi K, Suttmann H, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014;17:34\u20139.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"180_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","volume":"65","author":"C Pezaro","year":"2014","unstructured":"Pezaro C, Omlin A, Lorente D, Rodrigues DN, Ferraldeschi R, Bianchini D, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014;65:270\u20133.","journal-title":"Eur Urol"},{"key":"180_CR6","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018;36:2492\u2013503.","journal-title":"J Clin Oncol"},{"key":"180_CR7","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol. 2008;26:1148\u201359.","journal-title":"J Clin Oncol"},{"key":"180_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4329\/wjr.v7.i8.202","volume":"7","author":"GJ O\u2019Sullivan","year":"2015","unstructured":"O\u2019Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: an update. World J Radiol. 2015;7:202\u201311.","journal-title":"World J Radiol"},{"key":"180_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2967\/jnumed.116.181800","volume":"58","author":"TA Hope","year":"2017","unstructured":"Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, et al. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med. 2017;58:81\u20134.","journal-title":"J Nucl Med"},{"key":"180_CR10","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s00259-017-3887-x","volume":"45","author":"AK Seitz","year":"2018","unstructured":"Seitz AK, Rauscher I, Haller B, Kr\u00f6nke M, Luther S, Heck MM, et al. Preliminary results on response assessment using 68 Ga-HBED-CC-PSMA PET\/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging. 2018;45:602\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"180_CR11","doi-asserted-by":"crossref","unstructured":"Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PEZ, Harzstark AL, Ferrone M, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-C-13]Pyruvate. Sci Transl Med. 2013;5:198ra108","DOI":"10.1126\/scitranslmed.3006070"},{"key":"180_CR12","doi-asserted-by":"publisher","first-page":"10158","DOI":"10.1073\/pnas.1733835100","volume":"100","author":"JH Ardenkjaer-Larsen","year":"2003","unstructured":"Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, et al. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc Natl Acad Sci USA. 2003;100:10158\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"key":"180_CR13","doi-asserted-by":"publisher","first-page":"8607","DOI":"10.1158\/0008-5472.CAN-08-0749","volume":"68","author":"MJ Albers","year":"2008","unstructured":"Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang VY, et al. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008;68:8607\u201315.","journal-title":"Cancer Res"},{"key":"180_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neo.2018.09.006","volume":"21","author":"J Kurhanewicz","year":"2018","unstructured":"Kurhanewicz J, Vigneron DB, Ardenkjaer-Larsen JH, Bankson JA, Brindle K, Cunningham CH, et al. Hyperpolarized (13)C MRI: path to clinical translation in oncology. Neoplasia. 2018;21:1\u201316.","journal-title":"Neoplasia"},{"key":"180_CR15","doi-asserted-by":"publisher","first-page":"6921","DOI":"10.1158\/0008-5472.CAN-11-1457","volume":"71","author":"F Hirschhaeuser","year":"2011","unstructured":"Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res. 2011;71:6921\u20135.","journal-title":"Cancer Res"},{"key":"180_CR16","doi-asserted-by":"publisher","first-page":"8927","DOI":"10.1158\/0008-5472.CAN-06-1501","volume":"66","author":"JW Kim","year":"2006","unstructured":"Kim JW, Dang CV. Cancer\u2019s molecular sweet tooth and the Warburg effect. Cancer Res. 2006;66:8927\u201330.","journal-title":"Cancer Res"},{"key":"180_CR17","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41586-018-0729-3","volume":"563","author":"PS Gonzalez","year":"2018","unstructured":"Gonzalez PS, O\u2019Prey J, Cardaci S, Barthet VJA, Sakamaki JI, Beaumatin F, et al. Mannose impairs tumour growth and enhances chemotherapy. Nature. 2018;563:719\u201323.","journal-title":"Nature"},{"key":"180_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-33","volume":"9","author":"M Zhou","year":"2010","unstructured":"Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O, et al. Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer. 2010;9:33.","journal-title":"Mol Cancer"},{"key":"180_CR19","doi-asserted-by":"publisher","first-page":"5196","DOI":"10.1158\/1078-0432.CCR-16-0159","volume":"22","author":"KN Timm","year":"2016","unstructured":"Timm KN, Kennedy BW, Brindle KM. Imaging tumor metabolism to assess disease progression and treatment response. Clin Cancer Res. 2016;22:5196\u2013203.","journal-title":"Clin Cancer Res"},{"key":"180_CR20","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.eururo.2017.07.022","volume":"72","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, Vigneron DB, Kurhanewicz J. Hyperpolarized 1-[(13)C]-pyruvate magnetic resonance imaging detects an early metabolic response to androgen ablation therapy in prostate cancer. Eur Urol. 2017;72:1028\u20139.","journal-title":"Eur Urol"},{"key":"180_CR21","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1002\/mrm.27179","volume":"80","author":"HY Chen","year":"2018","unstructured":"Chen HY, Larson PEZ, Gordon JW, Bok RA, Ferrone M, van Criekinge M, et al. Technique development of 3D dynamic CS-EPSI for hyperpolarized (13) C pyruvate MR molecular imaging of human prostate cancer. Magn Reson Med. 2018;80:2062\u201372.","journal-title":"Magn Reson Med"},{"key":"180_CR22","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/mrm.27077","volume":"80","author":"I Park","year":"2018","unstructured":"Park I, Larson PEZ, Gordon JW, Carvajal L, Chen HY, Bok R, et al. Development of methods and feasibility of using hyperpolarized carbon-13 imaging data for evaluating brain metabolism in patient studies. Magn Reson Med. 2018;80:864\u201373.","journal-title":"Magn Reson Med"},{"key":"180_CR23","doi-asserted-by":"publisher","unstructured":"Brender JR, Kishimoto S, Merkle H, Reed G, Hurd RE, Chen AP, et al. PET by MRI: Glucose Imaging by 13C-MRS without dynamic nuclear polarization by noise suppression through tensor decomposition rank reduction. bioRxiv. 2018; preprint 15 February 2018; \nhttps:\/\/doi.org\/10.1101\/265793\n\n.","DOI":"10.1101\/265793"},{"key":"180_CR24","first-page":"95","volume":"84","author":"SJ Nelson","year":"1989","unstructured":"Nelson SJ, Brown TR. The accuracy of quantification from 1d nmr-spectra using the piqable algorithm. J Magn Reson. 1989;84:95\u2013109.","journal-title":"J Magn Reson"},{"key":"180_CR25","doi-asserted-by":"publisher","first-page":"e3997","DOI":"10.1002\/nbm.3997","volume":"31","author":"PEZ Larson","year":"2018","unstructured":"Larson PEZ, Chen HY, Gordon JW, Korn N, Maidens J, Arcak M, et al. Investigation of analysis methods for hyperpolarized 13C-pyruvate metabolic MRI in prostate cancer patients. NMR Biomed. 2018;31:e3997.","journal-title":"NMR Biomed"},{"key":"180_CR26","unstructured":"Korn N, Larson PEZ, Chen H-Y, Gordon JW, Bok RA, Van Criekinge M, et al. The rate of hyperpolarized [1-13C] pyruvate to [1-13C] lactate conversion distinguishes high-grade prostate cancer from low-grade prostate cancer and normal peripheral zone tissue in patients. Proceedings of the 26th Annual Meeting of ISMRM, Paris France. 2018; International Society for Magnetic Resonance in Medicine."},{"key":"180_CR27","doi-asserted-by":"publisher","unstructured":"Mammoli D, Gordon J, Autry A, Larson PEZ, Li Y, Chen HY, et al. Kinetic modeling of hyperpolarized carbon-13 pyruvate metabolism in the human brain. IEEE Trans Med Imaging. 2019; e-pub ahead of print 2 July 2019; \nhttps:\/\/doi.org\/10.1109\/TMI.2019.2926437\n\n.","DOI":"10.1109\/TMI.2019.2926437"},{"key":"180_CR28","doi-asserted-by":"crossref","unstructured":"Bok R, Lee J, Sriram R, Keshari K, Sukumar S, Daneshmandi S, et al. The role of lactate metabolism in prostate cancer progression and metastases revealed by dual-agent hyperpolarized (13)C MRSI. Cancers. 2019;11:257.","DOI":"10.3390\/cancers11020257"},{"key":"180_CR29","doi-asserted-by":"crossref","unstructured":"Hiew K, Hart CA, Ali A, Elliott T, Ramani V, Sangar V, et al. Primary mutational landscape linked with pre-docetaxel lactate dehydrogenase levels predicts docetaxel response in metastatic castrate-resistant prostate cancer. Eur Urol Focus. 2019;5:831\u201341.","DOI":"10.1016\/j.euf.2018.04.006"},{"key":"180_CR30","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1038\/bjc.2014.158","volume":"110","author":"MI Koukourakis","year":"2014","unstructured":"Koukourakis MI, Giatromanolaki A, Panteliadou M, Pouliliou SE, Chondrou PS, Mavropoulou S, et al. Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy. Br J Cancer. 2014;110:2217\u201323.","journal-title":"Br J Cancer"},{"key":"180_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","volume":"1","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, et al. Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer. Eur Urol Oncol. 2018;1:78\u201382.","journal-title":"Eur Urol Oncol"},{"key":"180_CR32","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2967\/jnumed.117.191031","volume":"58","author":"SM Schwarzenboeck","year":"2017","unstructured":"Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, et al. PSMA Ligands for PET imaging of prostate cancer. J Nucl Med. 2017;58:1545\u201352.","journal-title":"J Nucl Med"},{"key":"180_CR33","doi-asserted-by":"crossref","unstructured":"Heiken JP, Bae KT. Contrast medium administration and scan timing for MDCT.\u00a0 In: Marchal G, Vogl TJ, Heiken JP, Rubin GD (eds). Multidetector-Row Computed Tomography, Springer: New York 2005, pp 13\u201320.","DOI":"10.1007\/88-470-0363-6_3"},{"key":"180_CR34","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s13244-012-0196-6","volume":"3","author":"F Davnall","year":"2012","unstructured":"Davnall F, Yip CS, Ljungqvist G, Selmi M, Ng F, Sanghera B, et al. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging. 2012;3:573\u201389.","journal-title":"Insights Imaging"},{"key":"180_CR35","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","volume":"93","author":"M Hockel","year":"2001","unstructured":"Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"180_CR36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487\u201395.","journal-title":"Cancer Discov"},{"key":"180_CR37","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/S1470-2045(14)71021-6","volume":"15","author":"E Lalonde","year":"2014","unstructured":"Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol. 2014;15:1521\u201332.","journal-title":"Lancet Oncol"},{"key":"180_CR38","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1007\/s00259-008-0788-z","volume":"35","author":"M Beheshti","year":"2008","unstructured":"Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35:1766\u201374.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"180_CR39","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s00259-005-1842-8","volume":"32","author":"T Nakai","year":"2005","unstructured":"Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005;32:1253\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"180_CR40","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1200\/JCO.1998.16.10.3375","volume":"16","author":"GJ Cook","year":"1998","unstructured":"Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375\u20139.","journal-title":"J Clin Oncol"},{"key":"180_CR41","doi-asserted-by":"publisher","first-page":"838202","DOI":"10.1155\/2015\/838202","volume":"2015","author":"T Todenhofer","year":"2015","unstructured":"Todenhofer T, Stenzl A, Hofbauer LC, Rachner TD. Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies. Int J Endocrinol. 2015;2015:838202.","journal-title":"Int J Endocrinol"},{"key":"180_CR42","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/mrm.27743","volume":"82","author":"AW Autry","year":"2019","unstructured":"Autry AW, Gordon JW, Carvajal L, Mareyam A, Chen HY, Park I, et al. Comparison between 8\u2010and 32\u2010channel phased\u2010array receive coils for in vivo hyperpolarized 13C imaging of the human brain. Magn Reson Med. 2019;82:833\u201341.","journal-title":"Magn Reson Med"},{"key":"180_CR43","doi-asserted-by":"crossref","unstructured":"Gordon JW, Chen HY, Autry A, Park I, Van Criekinge M, Mammoli D, et al. Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients. Magn Reson Med. 2019;81:2702\u20139.","DOI":"10.1002\/mrm.27549"},{"key":"180_CR44","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.eururo.2011.07.060","volume":"60","author":"P Rigatti","year":"2011","unstructured":"Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, et al. Pelvic\/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography\/computed tomography. Eur Urol. 2011;60:935\u201343.","journal-title":"Eur Urol"},{"key":"180_CR45","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446\u201353.","journal-title":"J Clin Oncol"},{"key":"180_CR46","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/cncr.31860","volume":"125","author":"CC Foster","year":"2019","unstructured":"Foster CC, Weichselbaum RR, Pitroda SP. Oligometastatic prostate cancer: reality or figment of imagination? Cancer. 2019;125:340\u201352.","journal-title":"Cancer"},{"key":"180_CR47","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630\u201342.","journal-title":"Eur Urol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0180-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0180-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0180-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:34:24Z","timestamp":1684618464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-019-0180-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["180"],"URL":"https:\/\/doi.org\/10.1038\/s41391-019-0180-z","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,4]]},"assertion":[{"value":"21 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}